Literature DB >> 7597269

The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy.

J Congleton1, M F Muers.   

Abstract

Breathlessness is a common symptom in patients with primary bronchial carcinoma and is often not well-controlled. Most patients are ex- or current smokers, and therefore are at high risk for co-existing chronic obstructive pulmonary disease (COPD). The incidence of airflow obstruction in patients with bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy was examined prospectively. Fifty-seven consecutive patients attending our outpatient clinic with bronchial carcinoma diagnosed in the preceding 12 months were studied (22 female, 35 male, mean age 68.4 years). Spirometry was performed and breathlessness rated. Those with airflow obstruction (FEV1:FVC < 65% and FEV1 < 70% predicted) and who judged themselves to have moderate or severe breathlessness, were offered a trial of bronchodilator therapy. The response to regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer, and to regular nebulized salbutamol and ipratropium bromide was assessed by home peak flow recordings, spirometry and two subjective scores: (a) rating of breathlessness on a simple four-point scale, and (b) activity score of the St George's Respiratory Questionnaire. There was very strong association between airflow obstruction and breathlessness. Twenty-eight patients (49%) had airflow obstruction, and we had breathlessness ratings on 26 of these patients of whom 18 (69%) had rated it as moderate or severe. Only four of the patients with airflow obstruction and breathlessness were using bronchodilator therapy. There was no significant difference in the mean age, time from diagnosis, tumour site, or smoking history between the groups with, and without, airflow obstruction. There was no association between cell type and the presence of airflow obstruction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597269     DOI: 10.1016/0954-6111(95)90090-x

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  16 in total

1.  COPD Overlap Syndromes: Asthma and Beyond.

Authors:  Allison A Lambert; Mark T Dransfield
Journal:  Chronic Obstr Pulm Dis       Date:  2016-01-15

2.  Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna.

Authors:  Gudrun Pohl; Christine Marosi; Karin Dieckmann; Gregor Goldner; Katarzyna Elandt; Marco Hassler; Michael Schemper; Kathrin Strasser-Weippl; Friedemann Nauck; Jan Gaertner; Herbert Watzke
Journal:  Wien Med Wochenschr       Date:  2012-01

3.  Underdetection and Undertreatment of Dyspnea in Critically Ill Patients.

Authors:  Eliza R Gentzler; Heather Derry; Daniel J Ouyang; Lindsay Lief; David A Berlin; Cici Jiehui Xu; Paul K Maciejewski; Holly G Prigerson
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

4.  COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma.

Authors:  A Papi; G Casoni; G Caramori; I Guzzinati; P Boschetto; F Ravenna; N Calia; S Petruzzelli; L Corbetta; G Cavallesco; E Forini; M Saetta; A Ciaccia; L M Fabbri
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

Review 5.  Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment.

Authors:  Yasuo Sekine; Atsushi Hata; Eitetsu Koh; Kenzo Hiroshima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-03-14

Review 6.  Management of specific symptom complexes in patients receiving palliative care.

Authors:  E Bruera; C M Neumann
Journal:  CMAJ       Date:  1998-06-30       Impact factor: 8.262

7.  Dyspnoea worsened by salmeterol.

Authors:  John Fraser
Journal:  J R Soc Med       Date:  2002-11       Impact factor: 18.000

Review 8.  Biomarkers in Exhaled Breath Condensate and Serum of Chronic Obstructive Pulmonary Disease and Non-Small-Cell Lung Cancer.

Authors:  Mann Ying Lim; Paul S Thomas
Journal:  Int J Chronic Dis       Date:  2013-08-01

9.  Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors.

Authors:  José Luis Izquierdo; Pilar Resano; Abdulkader El Hachem; Desiré Graziani; Carlos Almonacid; Ignacio M Sánchez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-09-30

Review 10.  Akt in the pathogenesis of COPD.

Authors:  Steven Bozinovski; Ross Vlahos; Michelle Hansen; Ken Liu; Gary P Anderson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.